Osseocare Pro Console & Set Osseocare Pro, Model 1600870-001, 1700470-001, and 1700471-001. De...
FDA Device Recall #Z-0273-2014 — Class II — October 24, 2013
Recall Summary
| Recall Number | Z-0273-2014 |
| Classification | Class II — Moderate risk |
| Date Initiated | October 24, 2013 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Nobel Biocare Usa Llc |
| Location | Yorba Linda, CA |
| Product Type | Devices |
| Quantity | 1082 (391 US) |
Product Description
Osseocare Pro Console & Set Osseocare Pro, Model 1600870-001, 1700470-001, and 1700471-001. Device Name: Osseocare Pro console & Set Osseocare Pro. Model: 1600870-001, 1700470-001, 1700471-001. Marketing status: Class I, under K092214. Device description: Software-based, electronically controlled tabletop device. In dentistry for dental surgery, endodontics and implantology.
Reason for Recall
The recall was initiated because there is a potential for malfunction of the OsseoCare Pro when used with the OseeoCare Pro iPad application software release 1.2.0.7.
Distribution Pattern
Worldwide Distribution - USA (nationwide) United States and Internationally to Austria, Belgium, Brazil, Canada, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, India, Ireland, Italy, Japan, Latvia, Lithuania, Luxembourg, Mexico, Netherlands, Norway, Philippines, Poland, Portugal, Romania, Russia, South Africa, Spain, Sweden, Switzerland, Turkey, and the United Kingdom.
Lot / Code Information
Model Numbers: 1600870-001, 1700470-001, 1700471-001.
Other Recalls from Nobel Biocare Usa Llc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-0658-2022 | Class II | NobelReplace Conical Connection RP 4.3x11.5 mm ... | Dec 17, 2021 |
| Z-1851-2020 | Class II | NobelParallel Conical Connection NP, 3.75x10mm ... | Aug 28, 2019 |
| Z-1853-2020 | Class II | Temporary Abutment Engaging CC RP pre-manufactu... | Aug 9, 2019 |
| Z-1854-2020 | Class II | Esthetic Abutment CC RP 1.5 mm pre-manufactured... | Aug 9, 2019 |
| Z-1856-2020 | Class II | Universal Base CC RP 1.5 mm; The Universal Base... | Aug 9, 2019 |
Frequently Asked Questions
A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.